Literature DB >> 17317541

Cardiovascular protection of nonmitogenic human acidic fibroblast growth factor from oxidative damage in vitro and in vivo.

Xiao-Kun Li1, Zhuo-Feng Lin, Yan Li, Shifeng Hu, Yi Tan, Zhifeng Huang, Juan Meng, Li-Ming Liang, Jian Xiao, Jia Qu, Lu Cai.   

Abstract

BACKGROUND: In our previous study, a mutant human acidic fibroblast growth factor without mitogenic action (nonmitogenic human acidic fibroblast growth factor) was created, and its protection from the cytotoxic effect of hydrogen peroxide treatment was confirmed in cultured cardiomyocytes.
METHODS: The present study was performed to further investigate whether genetically overexpressing nonmitogenic human acidic fibroblast growth factor in cardiomyocytes provides similar protection from the cytotoxic effect of hydrogen peroxide and whether in vivo administration of nonmitogenic human acidic fibroblast growth factor attenuates ischemia/reperfusion-induced cardiac dysfunction and tissue damage and protects the carotid sinus baroreceptor from alcohol-induced damage, as shown by a reduced response of blood pressure to short carotid artery occlusion. RESULTS AND
CONCLUSIONS: Cardiomyocytes transfected by nonmitogenic human acidic fibroblast growth factor, with significant increases in the cellular expression and secretion of nonmitogenic human acidic fibroblast growth factor into a culture medium, were resistant to hydrogen-peroxide-induced cytotoxicity, as measured by cell viability. Hearts isolated from rats pretreated with saline, human acidic fibroblast growth factor, or nonmitogenic human acidic fibroblast growth factor for 24 h were subjected to ischemia/reperfusion in the Langendorff system. Ischemia/reperfusion induced cardiac dysfunction in the saline group, but not in the group pretreated with human acidic fibroblast growth factor or nonmitogenic human acidic fibroblast growth factor. Ischemia/reperfusion also caused a release of the cardiac enzyme lactic dehydrogenase into-and an increase in lipid peroxide content in the efflux of-the hearts of saline-treated rats, but not in rats pretreated with human acidic fibroblast growth factor or nonmitogenic human acidic fibroblast growth factor. There was no difference in cardioprotective effects between human acidic fibroblast growth factor and nonmitogenic human acidic fibroblast growth factor. Furthermore, the protective effect of in-vivo-administered nonmitogenic acidic fibroblast growth factor on alcohol-induced damage to the carotid sinus baroreceptor, as shown by the reduced response of blood pressure to short carotid artery occlusion, was also observed. These results suggest that nonmitogenic human acidic fibroblast growth factor, similar to the native human acidic fibroblast growth factor, provides significant cardiovascular protection from oxidative damage in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317541     DOI: 10.1016/j.carpath.2006.11.004

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  3 in total

1.  A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration.

Authors:  Chahua Huang; Yang Liu; Andrew Beenken; Lin Jiang; Xiang Gao; Zhifeng Huang; Anna Hsu; Garrett J Gross; Yi-Gang Wang; Moosa Mohammadi; Jo El J Schultz
Journal:  Cardiovasc Res       Date:  2017-11-01       Impact factor: 10.787

Review 2.  Fibroblast Growth Factor in Diabetic Foot Ulcer: Progress and Therapeutic Prospects.

Authors:  Ye Liu; Yiqiu Liu; Junyu Deng; Wei Li; Xuqiang Nie
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-14       Impact factor: 5.555

3.  Fibroblast Growth Factor 1 Reduces Pulmonary Vein and Atrium Arrhythmogenesis via Modification of Oxidative Stress and Sodium/Calcium Homeostasis.

Authors:  Yen-Yu Lu; Chen-Chuan Cheng; Shih-Yu Huang; Yao-Chang Chen; Yu-Hsun Kao; Yung-Kuo Lin; Satoshi Higa; Shih-Ann Chen; Yi-Jen Chen
Journal:  Front Cardiovasc Med       Date:  2022-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.